Dr. Michael Schweizer
Claim this profileFred Hutch/University of Washington Cancer Consortium
Expert in Prostate Cancer
Studies Prostate Adenocarcinoma
14 reported clinical trials
27 drugs studied
Area of expertise
1Prostate Cancer
Global LeaderStage IV
HR positive
CDK12 positive
2Prostate Adenocarcinoma
HR positive
CDK12 positive
MSI-H positive
Affiliated Hospitals
Clinical Trials Michael Schweizer is currently running
Radioligand Therapy
for Prostate Cancer
The purpose of this study is to evaluate the change in the expression of treatment targets on the surface of tumor cells (Prostate Specific Membrane Antigen (PSMA), Somatostatin Receptor 2 (SSTR2), and Gastrin Releasing Peptide Receptor (GRPR) between the baseline and following targeted radioligand therapy (RLT). Study will use radioligand imaging (RLI) to determine predominantly expressed target on the surface of tumor cells. Based on predominant expression of target, corresponding RLT targeting PSMA, SSTR2, or GRPR RLT will be given for up to 6 cycles every 6 weeks as intravenous (i.v.) injection in participants with metastatic neuroendocrine prostate cancer (mNEPC). Study is planning to enroll approximately 20 participants in \[177Lu\]Lu-PSMA-617 treatment arm, approximately 3 participants in \[177Lu\]Lu-NeoB treatment arm, and approximately 13 participants in \[177Lu\]Lu-DOTA-TATE treatment arm.
Recruiting1 award Phase 14 criteria
High-Dose Testosterone + Chemotherapy
for Prostate Cancer
This trial tests if high levels of a hormone combined with cancer treatment can help treat prostate cancer that has spread and is not responding to usual treatments. The hormone may damage cancer cell DNA, and the treatment helps kill or slow the cancer cells.
Recruiting1 award Phase 220 criteria
More about Michael Schweizer
Clinical Trial Related1 year of experience running clinical trials · Led 14 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Michael Schweizer has experience with
- Olaparib
- Docetaxel
- Enzalutamide
- Durvalumab
- Carboplatin
- Etoposide
Breakdown of trials Michael Schweizer has run
Prostate Cancer
Prostate Adenocarcinoma
Prostate Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael Schweizer specialize in?
Michael Schweizer focuses on Prostate Cancer and Prostate Adenocarcinoma. In particular, much of their work with Prostate Cancer has involved Stage IV patients, or patients who are HR positive.
Is Michael Schweizer currently recruiting for clinical trials?
Yes, Michael Schweizer is currently recruiting for 6 clinical trials in Seattle Washington. If you're interested in participating, you should apply.
Are there any treatments that Michael Schweizer has studied deeply?
Yes, Michael Schweizer has studied treatments such as Olaparib, Docetaxel, Enzalutamide.
What is the best way to schedule an appointment with Michael Schweizer?
Apply for one of the trials that Michael Schweizer is conducting.
What is the office address of Michael Schweizer?
The office of Michael Schweizer is located at: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington 98109 United States. This is the address for their practice at the Fred Hutch/University of Washington Cancer Consortium.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.